Josh Hardman

... psychedelic drug developers; and his broader outlook on the field. (Editor's note: Given the length of this interview, we decided that—rather than ...

Psychedelic Alpha’s Josh Hardman speaks with Compass Pathways CEO, Kabir Nath, about a range of topics: from the company’s recently-announced agreements that could shed light...

In this episode, Josh Hardman, the founder of Psychedelic Alpha, explores the multitude of challenges currently being encountered by the psychedelic industry. He engages in...

Written by Psychedelic Alpha Medical Advisor Michael Haichin, PharmD, and Josh Hardman as part of the Pα+ Library. As we look ahead to potential approvals...

Psychedelic Alpha’s Josh Hardman searches online message boards and chat rooms to hear from those who claim to have tried Tabernanthalog (TBG), a ‘non-hallucinogenic’ ibogaine...

The raising of interest rates this week by the Federal Reserve by a quarter percentage point was anticipated by investors and economists who hope that...

Back in the spine-tingling hysteria of the dotcom boom in the late 1990’s, when investors threw dump trucks of money at dotcom startups, I sat...

In 2010, a Dutch philosophy undergraduate called Martijn Schirp almost won the World Series of Poker in Las Vegas, in which 7,400 players competed for...

This week Shayla Love reports in Lucid News that there has been an increase in the number of patents filed for psychedelic therapies and compounds....

Now in its 15th year, the Horizons: Perspectives on Psychedelics conference returns October 12-15 to the New York Academy of Medicine and The Great Hall...